TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9729573

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (6 mg/kg)
Number of subjects: 9
Study: 8002329

Group type: EXPERIMENTAL
Intervention: 0.25 mg of sublingual apomorphine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3261951

Group type: EXPERIMENTAL
Intervention: Tightly fitting face mask
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oxygen flow of 10 l/min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Duration of preoxygenation (5 min)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SaO2
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CaO2
Number of subjects: 80
Study: 7802151

Group type: EXPERIMENTAL
Intervention: Group I (AE): alfentanil 30 micrograms/kg and etomidate 0.3 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group II (AP): alfentanil 30 micrograms/kg and propofol 1.5 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group III (SE): sufentanil 0.3 microgram/kg and etomidate 0.3 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group IV (SP): sufentanil 0.3 microgram/kg and propofol 1.5 mg/kg
Number of subjects: 80
Study: 42593

Group type: EXPERIMENTAL
Intervention: 25 mg of quazepam (Sch-16134)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31071147

Group type: EXPERIMENTAL
Intervention: Viewing or being immersed in father-friendly prenatal care office cues (online videos or in-person visits)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 0
Study: 28486629

Group type: EXPERIMENTAL
Intervention: Caudal block with ropivacaine 0.15%, 1.5 ml kg ‐1 (High-Volume group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Caudal block with ropivacaine 0.15%, 1.0 ml kg ‐1 (Low-Volume group)
Number of subjects: 80
Study: 26419732

Group type: EXPERIMENTAL
Intervention: Anticholinergic medication exposure
Number of subjects: 99
Study: 23301757

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (PIP/TAZO) plus amikacin (AMK)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cefoperazone-sulbactam (CS) plus amikacin (AMK)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (PIP/TAZO+AMK and CS+AMK)
Number of subjects: 46
Study: 21160054

Group type: EXPERIMENTAL
Intervention: Applied behaviour analysis by a specialist team plus standard treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone (control)
Number of subjects: 0
Study: 19359073

Group type: EXPERIMENTAL
Intervention: L-arginine (14 g/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 16754923

Group type: EXPERIMENTAL
Intervention: No additional diagnostic testing for PE (experimental intervention)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Additional diagnostic testing (control intervention)
Number of subjects: 1126
Study: 15167306

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 11308049

Group type: EXPERIMENTAL
Intervention: rhGH (Genotropin) at a dose of 0.2 IU/kg/day as daily s.c. injections for two years
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 26
Study: 9329513

Group type: EXPERIMENTAL
Intervention: zidovudine plus didanosine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: zidovudine plus zalcitabine
Number of subjects: 240

Group type: COMPARATOR
Intervention: zidovudine only
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: zidovudine plus didanosine and zidovudine plus zalcitabine
Number of subjects: 240

Group type: COMPARATOR
Intervention: zidovudine monotherapy
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combined-therapy groups
Number of subjects: 240
Study: 7950213

Group type: EXPERIMENTAL
Intervention: Alkaline extract of Euphorbia fisheriana (EF)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Single-blind treatment with EF
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 3665359

Group type: EXPERIMENTAL
Intervention: LSL group (ipsilateral limb)
Number of subjects: 16

Group type: COMPARATOR
Intervention: LOL group (contralateral limb)
Number of subjects: 16
Study: 31838642

Group type: EXPERIMENTAL
Intervention: Amino acid supplementation with rehabilitation program (5 sessions of 40 min/week for 2 weeks, followed by home-based exercise protocol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rehabilitation program (5 sessions of 40 min/week for 2 weeks, followed by home-based exercise protocol)
Number of subjects: 20
Study: 31229401

Group type: EXPERIMENTAL
Intervention: Deferasirox alone (30 mg/kg daily)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Deferasirox and deferoxamine combination (30 mg/kg deferasirox daily plus SC 50 mg/kg deferoxamine for 5 days a week)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Deferasirox and deferoxamine combination
Number of subjects: 62

Group type: COMPARATOR
Intervention: Deferasirox alone
Number of subjects: 62
Study: 26890193

Group type: EXPERIMENTAL
Intervention: BoNT‐A injection plus three ESWT sessions
Number of subjects: 10

Group type: COMPARATOR
Intervention: BoNT‐A alone
Number of subjects: 10
Study: 25405276

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.1 ml kg(‐1) h(‐1) during ERCP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Fentanyl (200 μg before ERCP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (intranasal placebo before ERCP and placebo during ERCP)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: All groups (R, F, P)
Number of subjects: 180
Study: 23234763

Group type: EXPERIMENTAL
Intervention: Lapatinib (1500 mg daily for 12 months)
Number of subjects: 3161

Group type: COMPARATOR
Intervention: Placebo (daily for 12 months)
Number of subjects: 3161
Study: 21513687

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 162

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 162
Study: 18164689

Group type: EXPERIMENTAL
Intervention: Presentation times of 10, 50, 202, and 3000 ms (Experiment 1) plus unlimited presentation time (Experiment 2)
Number of subjects: 0
Study: 16496099

Group type: EXPERIMENTAL
Intervention: Running suture technique with slowly absorbable monofilament suture material (PDS)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Interrupted technique with a braided, rapidly absorbable suture material (Vicryl)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Course organisation, content, and speaker evaluation during the surgical investigator meeting
Number of subjects: 625
Study: 12091295

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (100 microg four times daily for 10 days via Aerochamber)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Systemic dexamethasone (0.5 mg/kg/day, reducing over nine days)
Number of subjects: 16
Study: 9916960

Group type: EXPERIMENTAL
Intervention: Burch retropubic urethropexy
Number of subjects: 35
Study: 7743790

Group type: EXPERIMENTAL
Intervention: Quality assessment scales
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Checklists for reporting RCTs
Number of subjects: 0
Study: 2200237

Group type: EXPERIMENTAL
Intervention: Oat bran muffins (4 per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Delayed intervention group (control)
Number of subjects: 16
Study: 6821438

Group type: EXPERIMENTAL
Intervention: Deanol acetamidobenzoate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Orphenadrine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 29764965

Group type: EXPERIMENTAL
Intervention: Tight control treatment aiming for SDAI remission (SDAI ≤ 3.3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tight control treatment aiming for DAS28 remission (DAS28 < 2.6)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Achieving sustained DAS28 remission
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Posthoc analysis including all 110 patients with PWV
Number of subjects: 120
Study: 27153835

Group type: EXPERIMENTAL
Intervention: Beardslee's Preventive Intervention Program (PIP), delivered in seven weekly sessions at the family home.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group following treatment as usual.
Number of subjects: 0
Study: 25274500

Group type: EXPERIMENTAL
Intervention: Back School and Heart Coherence Training (BS-HCT)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Back School (BS)
Number of subjects: 170
Study: 22476829

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (RYGB)
Number of subjects: 240
Study: 20705782

Group type: EXPERIMENTAL
Intervention: Single injection of lidocaine 2% 30 mL
Number of subjects: 100

Group type: COMPARATOR
Intervention: Triple injection adjacent to each brachial plexus cord
Number of subjects: 100
Study: 17631626

Group type: EXPERIMENTAL
Intervention: Comprehensive violence prevention program
Number of subjects: 1788

Group type: EXPERIMENTAL
Intervention: School perceived as safe
Number of subjects: 1788

Group type: EXPERIMENTAL
Intervention: Individual risk factors (being male, childhood maltreatment, poor parental nurturing)
Number of subjects: 1788
Study: 16255952

Group type: EXPERIMENTAL
Intervention: Early administration of NPPV plus standard medical treatment (group B)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Standard medical treatment (group A)
Number of subjects: 342
Study: 12135994

Group type: EXPERIMENTAL
Intervention: Higher client fees for family planning and reproductive health services
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Price increases at tested levels
Number of subjects: 15
Study: 10088941

Group type: EXPERIMENTAL
Intervention: Oxaceprol (200 mg three times daily)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Diclofenac (25 mg three times daily)
Number of subjects: 150
Study: 7562088

Group type: EXPERIMENTAL
Intervention: Alcohol treatment (30 g/d)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No alcohol treatment (energy replaced with carbohydrate)
Number of subjects: 37
Study: 1705137

Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg three times daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Toloxatone (400-200-400 mg day-1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6450544

Group type: EXPERIMENTAL
Intervention: Oxygen/nitrous oxide sedation (relative analgesia) with diazepam premedication 0.2 mg/kg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oxygen/nitrous oxide sedation
Number of subjects: 50
Study: 31134784

Group type: EXPERIMENTAL
Intervention: Robotic therapy training for 8 weeks, 16 sessions, combined with conventional therapy 5 days a week
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 88
Study: 28422001

Group type: EXPERIMENTAL
Intervention: 12 cyclophosphamide (CYC) pulses combined with glucocorticoids
Number of subjects: 64

Group type: COMPARATOR
Intervention: 6 cyclophosphamide (CYC) pulses combined with glucocorticoids
Number of subjects: 64
Study: 26690638

Group type: EXPERIMENTAL
Intervention: Power of Food Scale (PFS) score higher at baseline
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Power of Food Scale (PFS) score
Number of subjects: 294
Study: 23832170

Group type: EXPERIMENTAL
Intervention: E2/DRSP (1 mg estradiol + 2 mg drospirenone)
Number of subjects: 160

Group type: COMPARATOR
Intervention: E2/DG (1 mg estradiol + 5 mg dydrogesterone)
Number of subjects: 160
Study: 23165381

Group type: EXPERIMENTAL
Intervention: Oral theophylline anhydrous, 200 to 800 mg/d for 2 to 12 months
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intranasal theophylline methylpropyl paraben, 20 μg/d in each naris for 4 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Body weight measurement
Number of subjects: 10
Study: 20850055

Group type: EXPERIMENTAL
Intervention: Increased frequency of intake of fruits (F)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Increased frequency of intake of reduced-calorie snack foods (RCSF)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Higher initial frequency of intake of vegetables (V)
Number of subjects: 72
Study: 17437343

Group type: EXPERIMENTAL
Intervention: Routine oral calcium and vitamin D supplementation starting on postoperative day 1
Number of subjects: 487

Group type: COMPARATOR
Intervention: No routine oral calcium and vitamin D supplementation
Number of subjects: 487
Study: 15839866

Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 92
Study: 11865132

Group type: EXPERIMENTAL
Intervention: IV morphine (9-30 mg; mean dosage 16 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: IV morphine
Number of subjects: 15
Study: 10467608

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (30 mmol/d of leucine, isoleucine, and valine)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (30 mmol/d of glycine, serine, and alanine)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study: 1377036

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (total greater than 5 x 10(6) kallikrein inactivator units [KIU])
Number of subjects: 1784

Group type: COMPARATOR
Intervention: Control group (no aprotinin administration)
Number of subjects: 1784
Study: 6714602

Group type: EXPERIMENTAL
Intervention: New solution containing mainly sodium sulfate and polyethylene glycol (solution II)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Balanced standard electrolyte solution (solution I)
Number of subjects: 240
Study: 31375087

Group type: EXPERIMENTAL
Intervention: Rituximab (two 375 mg/m2 doses, maximum dose: 500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29468764

Group type: EXPERIMENTAL
Intervention: Hesperidin 500 mg/day
Number of subjects: 64
Study: 26731258

Group type: EXPERIMENTAL
Intervention: Insulin lispro (to induce low or high postprandial glycemia)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Nondiabetic controls
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Postprandial hyperglycemia in T2D patients
Number of subjects: 71
Study: 25711331

Group type: EXPERIMENTAL
Intervention: Early antiretroviral therapy (ART)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Deferred antiretroviral therapy (ART)
Number of subjects: 230
Study: 23685539

Group type: EXPERIMENTAL
Intervention: Entropy estimation of rapid cardiac rhythms preceding ICD shocks
Number of subjects: 119

Group type: COMPARATOR
Intervention: ICD shocks delivered for VT/ventricular fibrillation
Number of subjects: 119

Group type: COMPARATOR
Intervention: ICD shocks delivered for atrial fibrillation (AF)
Number of subjects: 119

Group type: COMPARATOR
Intervention: ICD shocks delivered for supraventricular tachycardia
Number of subjects: 119
Study: 20397880

Group type: EXPERIMENTAL
Intervention: Web-based course on Cognitive Behavioral Therapy (CBT)
Number of subjects: 174
Study: 17545193

Group type: EXPERIMENTAL
Intervention: 200 mg oral DHEA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16767613

Group type: COMPARATOR
Intervention: Generic aerobic interval training (running)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Specific aerobic interval training (small-sided games)
Number of subjects: 40
Study: 12760702

Group type: EXPERIMENTAL
Intervention: Cooled resin composite inserts
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Room-temperature resin composite inserts
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional bulk insertion (Control Group)
Number of subjects: 48
Study: 10948809

Group type: EXPERIMENTAL
Intervention: Topical nasal corticosteroids (flunisolide)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Antihistamine nasal spray (azelastine hydrochloride)
Number of subjects: 44
Study: 9408667

Group type: EXPERIMENTAL
Intervention: Early supported discharge service
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 92
Study: 8495154

Group type: EXPERIMENTAL
Intervention: Modified paediatric resuscitation chart
Number of subjects: 31

Group type: COMPARATOR
Intervention: Oakley chart
Number of subjects: 31
Study: 3542982

Group type: EXPERIMENTAL
Intervention: Rapid parenteral injections of fluphenazine hydrochloride
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral doses of fluphenazine hydrochloride
Number of subjects: 16
Study: 29504794

Group type: EXPERIMENTAL
Intervention: Emotion Regulation Therapy (ERT)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Modified Attention Control (MAC)
Number of subjects: 53
Study: 24947537

Group type: EXPERIMENTAL
Intervention: Economic support in the form of a voucher
Number of subjects: 0
Study: 22706942

Group type: EXPERIMENTAL
Intervention: Men with knee OA
Number of subjects: 33

Group type: COMPARATOR
Intervention: Women with knee OA
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both sexes (controlling for muscle volume)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both sexes (VA and contractile properties)
Number of subjects: 33
Study: 20532506

Group type: EXPERIMENTAL
Intervention: CVC insertion with skin colonisation monitoring
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Baseline colonisation
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 219
Study: 18499079

Group type: EXPERIMENTAL
Intervention: High signal salience condition
Number of subjects: 176

Group type: COMPARATOR
Intervention: Low signal salience condition
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Post-task self-reports of Task-Unrelated-Thoughts
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Post-task self-reports of Energetic Arousal
Number of subjects: 176
Study: 15705997

Group type: EXPERIMENTAL
Intervention: Zileuton (600 mg po qid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Zileuton
Number of subjects: 18
Study: 12837875

Group type: EXPERIMENTAL
Intervention: Encouragement from clinician to breastfeed
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Lack of confidence in ability to breastfeed
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Early breastfeeding problems
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Asian race/ethnicity
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Lower maternal education
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Maternal depressive symptoms
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Returning to work or school by 12 weeks postpartum
Number of subjects: 1163
Study: 10588556

Group type: EXPERIMENTAL
Intervention: 4% articaine without epinephrine
Number of subjects: 2
Study: 8755747

Group type: EXPERIMENTAL
Intervention: Autograft tricortical iliac crest bone
Number of subjects: 132

Group type: COMPARATOR
Intervention: Allograft bone
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 132
Study: 1540488

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6413114

Group type: EXPERIMENTAL
Intervention: Adriamycin (ADM) plus cisplatin (DDP)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: cisplatin regimens (various combinations)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group (DDP alone, thiotepa (TSPA) plus methotrexate (MTX))
Number of subjects: 273
Study: 31638334

Group type: EXPERIMENTAL
Intervention: Human urinary kallidinogenase (HUK) combined with butylphthalide (NBP)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Edaravone (Eda) combined with butylphthalide (NBP)
Number of subjects: 165
Study: 28486647

Group type: EXPERIMENTAL
Intervention: Intensive interdisciplinary pain treatment
Number of subjects: 0
Study: 26947239

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenges (DBPCFCs)
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Specific IgE results
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: DBPCFCs in children with mild, moderate, and severe AD
Number of subjects: 1186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Testing for food allergy
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Exacerbation of AD
Number of subjects: 1186
Study: 24385117

Group type: EXPERIMENTAL
Intervention: luliconazole cream 1%
Number of subjects: 256

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 256
Study: 22067762

Group type: EXPERIMENTAL
Intervention: Immediate insertion of LNG-IUD
Number of subjects: 88

Group type: COMPARATOR
Intervention: Delayed insertion of LNG-IUD
Number of subjects: 88
Study: 18626697

Group type: EXPERIMENTAL
Intervention: SWAL-QoL-NL
Number of subjects: 152
Study: 19126937

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 15189367

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol 50 microg 24 h(‐1) two times per week + medroxyprogesterone 2.5 mg day(‐1) + alfacalcidol 0.25 microg day(‐1) and calcium 1 g day(‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Alfacalcidol 0.25 microg day(‐1) and calcium 1 g day(‐1)
Number of subjects: 18
Study: 11898908

Group type: EXPERIMENTAL
Intervention: Prayer and distant healing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 9797792

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg orally once a day for 4 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7658310

Group type: EXPERIMENTAL
Intervention: rhEPO combined with adequate iron supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: i.v. iron combined with rhEPO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rhEPO given s.c.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose of 300 U/kg rhEPO in healthy non-pregnant volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: i.v. iron alone
Number of subjects: 0
Study: 2487544

Group type: EXPERIMENTAL
Intervention: naloxone (0.2 mg/kg) infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: saline infusion
Number of subjects: 12